Salvinorin A shows preclinical promise for pain, addiction, and stroke, but side effects and its brief action limit therapeutic potential

A systematic review of 82 animal studies suggests that salvinorin A, the main psychoactive compound in Salvia divinorum, may have therapeutic potential for pain, inflammation, addiction-related drug seeking, stroke, and related brain injuries. The review, led by Wolfgang Emanuel Zürrer at the University of Zurich, screened 1,718 publications and included about 3,456 animals, while only 10 studies supplied sufficiently comparable data for meta-analysis. Evidence for antidepressant effects was inconsistent, with some experiments showing benefits and others reporting depression-like responses. Safety findings were also mixed: anxiety-like behavior and impairments in movement and cognition occurred despite generally limited effects on heart rate and blood pressure. Salvinorin A acts primarily through kappa opioid receptors rather than the serotonin system targeted by psilocybin and LSD, but its effects peak rapidly and its brain half-life lasts roughly three to 36 minutes. Sixteen modified relatives may offer longer action, better brain penetration, or fewer behavioral side effects. The findings remain preliminary because human trials are scarce, study designs varied, and young male rodents dominated the evidence.